Merck sees 2022 sales up nearly 20%, mostly on molnupiravir
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Cantor Fitzgerald Reiterates Merck (MRK) at Overweight on Earnings, Pipeline and Growth "Remains Underappreciated"
February 3, 2022 7:44 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $107.00 price target on Merck (NYSE: MRK), following the company's Q4 earnings report.
The analyst quotes: "Post a 4Q21 sales and EPS beat, and ahead of a strong outlook for 2022, we are... More
